How effective is CES therapy?

The mechanism of action targets the pathogenesis of insomnia. It improves abnormal brain waves in anxiety patients, enhances previously low-intensity alpha waves, increases the secretion of 5-HT and gamma-aminobutyric acid (GABA), and improves various physiological indicators such as heart rate, blood pressure, and electromyography, effectively alleviating various physical symptoms of insomnia. Anruipu can also increase the secretion of endorphins, neurotransmitters with a calming effect, enabling patients to maintain a relaxed and comfortable mental state and alleviate insomnia symptoms.

 

Research on the etiology and pathogenesis of neurasthenia has found that emotional disorders are based on the structure of the central nervous system and bioactive neurochemicals. Decreased 5-HT activity, when serotonin levels are reduced, individual excitability decreases, leading to mental dullness and depressive mood. Furthermore, low levels of gamma-aminobutyric acid (GABA) weaken the inhibitory response to these responses, increasing the likelihood of insomnia and neurasthenia.

 

By increasing the secretion of 5-HT and γ-aminobutyric acid (GABA), Anrepu enhances the excitability of nerve cell activity, thereby alleviating individual depressive moods. By promoting the secretion of endorphins with sedative effects, Anrepu can help patients maintain a relaxed and comfortable mental state, which is beneficial for better alleviating previous negative and depressed moods. Furthermore, by improving patients' brain waves and various physiological indicators, Anrepu can improve various physical symptoms of neurasthenia patients.